In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Cost effectiveness of lung impedance-guided preemptive treatment in chronic heart failure patients in the outpatient clinic

Session Poster session 2 Sunday 08:30 - 18:00

Speaker Iris Dahan

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure- Treatment
  • Session type : Poster Session
  • FP Number : P762

Authors : I Dahan (Hadera,IL)

I Dahan1 , 1Hillel yaffe Medical center, Heart Institue - Hadera - Israel ,

On behalf: Iris Dahan, MSIT1, Avraham Shotan, MD1, Mark Kazatsker MD1, Lubov Vasilenko, MD1, Ilia Kleiner, MD2, Aya Asif MD1, David Blondhaim MD1, Simcha Meisel

European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 156

Recurrent hospitalizations in patients with congestive heart failure (CHF) represent a major financial burden for the health care system. We previously found that preemptive treatment based on monitoring lung impedance (LI) can prevent 55% of hospitalizations for acute heart failure (AHF).

Aim: To assess the effect of LI-guided therapy as compared with conventional treatment in patients admitted for AHF on the incidence and cost of recurrent hospitalizations.

Method and Results: 250 patients [(68 ± 11 years-old, male- 80%, LVEF- 28 ± 9%, initial NT-proBNP level- 3594 ± 5114 pg/ml, follow-up duration- 36 ± 22 months (7500 visits), NYHA II/III/IV (107/100/43)] were randomized to the LI-guided group 1 (n = 124) and group 2 (n = 126) who were treated by clinical assessment. Hospitalizations for AHF were recorded annually for both groups during 8-years of follow up. Hospitalizations per year were divided by number of patients followed that year and normalized to 100 patients. We estimated the average cost of AHF hospitalization as 18000$. Incidence of hospitalizations/100 patients during 1-8 year was 64, 31, 61, 57, 51, 15, 44, 77 in group 1 and 120, 68, 105, 111, 65, 73, 137, 150 in group 2 (p < 0.001). Cumulative savings for the health care system by using LI-guided therapy in 100 patients during the first 8 years was 1, 1.7, 2.5, 3.5, 3.7, 4.7, 6.4 and 7.7 $million, respectively. Cost of LI device for one patient was 1000$ for the first year and 500$ for each following year. The net profit of the health care system after 8 years of treatment was 7.7 million$ (saved hospitalizations) - 0.45 million$ (cost of devices with service) = 7.25 million$. Calculated net profit for one patient treated according LI for one year was 9063$.

Conclusion: The strategy of LI-guided therapy not only reduced significantly hospitalizations for AHF but also decreased the cost of therapy by 9063$/year for each patient.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are